PharVision Advisers LLC Acquires Shares of 6,192 Encompass Health Co. (NYSE:EHC)

PharVision Advisers LLC bought a new position in shares of Encompass Health Co. (NYSE:EHC - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 6,192 shares of the company's stock, valued at approximately $572,000. Encompass Health makes up 0.5% of PharVision Advisers LLC's portfolio, making the stock its 25th largest position.

A number of other large investors have also recently made changes to their positions in EHC. Park Avenue Securities LLC lifted its holdings in Encompass Health by 44.7% during the 4th quarter. Park Avenue Securities LLC now owns 6,737 shares of the company's stock worth $622,000 after purchasing an additional 2,082 shares in the last quarter. Merit Financial Group LLC bought a new stake in shares of Encompass Health during the fourth quarter valued at about $374,000. Ameritas Advisory Services LLC bought a new position in shares of Encompass Health in the fourth quarter valued at approximately $380,000. MassMutual Private Wealth & Trust FSB grew its stake in Encompass Health by 87.8% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company's stock valued at $27,000 after acquiring an additional 137 shares in the last quarter. Finally, Fort Washington Investment Advisors Inc. OH increased its holdings in Encompass Health by 0.3% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 302,272 shares of the company's stock worth $27,915,000 after acquiring an additional 830 shares during the period. 97.25% of the stock is owned by institutional investors.

Encompass Health Trading Up 0.1%

Shares of Encompass Health stock traded up $0.13 during trading on Monday, reaching $118.74. The company's stock had a trading volume of 388,011 shares, compared to its average volume of 699,207. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84. Encompass Health Co. has a 52-week low of $82.74 and a 52-week high of $121.96. The firm's 50-day moving average is $107.85 and its two-hundred day moving average is $101.40. The company has a market cap of $11.97 billion, a price-to-earnings ratio of 26.62, a PEG ratio of 2.31 and a beta of 0.91.

Encompass Health (NYSE:EHC - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $1.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.18. The business had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. The company's revenue was up 10.6% on a year-over-year basis. During the same period in the prior year, the business posted $1.12 earnings per share. On average, sell-side analysts anticipate that Encompass Health Co. will post 4.8 earnings per share for the current year.

Encompass Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Tuesday, July 1st will be issued a $0.17 dividend. This represents a $0.68 annualized dividend and a dividend yield of 0.57%. The ex-dividend date is Tuesday, July 1st. Encompass Health's dividend payout ratio is 14.05%.

Analysts Set New Price Targets

Several research analysts have commented on EHC shares. Royal Bank of Canada raised their price target on shares of Encompass Health from $110.00 to $125.00 and gave the company an "outperform" rating in a report on Monday, April 28th. UBS Group upped their target price on Encompass Health from $117.00 to $130.00 and gave the stock a "buy" rating in a research note on Monday, April 28th. Truist Financial reiterated a "buy" rating and set a $135.00 price target (up previously from $116.00) on shares of Encompass Health in a research report on Monday, April 28th. Wall Street Zen raised shares of Encompass Health from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Finally, William Blair reissued an "outperform" rating on shares of Encompass Health in a report on Friday, February 7th. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $120.86.

Insider Buying and Selling at Encompass Health

In other Encompass Health news, insider Elissa Joy Charbonneau sold 4,279 shares of the firm's stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $116.61, for a total value of $498,974.19. Following the completion of the sale, the insider now directly owns 11,958 shares in the company, valued at $1,394,422.38. This trade represents a 26.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Mark J. Tarr sold 118,384 shares of the company's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $121.53, for a total value of $14,387,207.52. Following the transaction, the chief executive officer now owns 527,070 shares in the company, valued at $64,054,817.10. This trade represents a 18.34% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 132,663 shares of company stock worth $16,034,082. 2.00% of the stock is currently owned by company insiders.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.